Abstract onlyVolume 27, Issue 6, Supplement S140June 2024
EE455 Cost-Effectiveness Analysis of Elacestrant in ER+/HER2- Advanced Breast Cancer Patient from US Payer Perspective
H Chan1 ∙ JJ Carlson2
1University of Washington, Baltimore, MD, USA
2University of Washington, Seattle, WA, USA
DOI: 10.1016/j.jval.2024.03.750Also available on ScienceDirect
To assess the cost-effectiveness of elacestrant compared to fulvestrant in second-line treatment for estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer from the US payer perspective.
Get full text access
Log in, subscribe or purchase for full access.
Article metrics
Metric data currently unavailableRelated articles (40)
- HTA17 Cost-Effectiveness Analysis of Capivasertib Plus Fulvestrant in Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Advanced Breast Cancer: A US Payer Perspective
- Liang et al.
Value in Health - First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis
- Lei et al.
Value in HealthAugust 1, 2024 - Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis
- Altawalbeh et al.
Value in HealthMarch 8, 2024
- Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States
- Mudumba et al.
Value in HealthNovember 30, 2023 - EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis
- Berrios et al.
Value in Health - EE183 Cost-Effectiveness Analysis of Early Versus Delayed Use of Abemaciclib Combination Treatment in Patients with HR+/HER2- High-Risk Early Breast Cancer: A US Payer Perspective
- Chang et al.
Value in Health - The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non–Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis
- Jansen et al.
Value in HealthSeptember 21, 2023 - Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data
- Lu et al.
Value in HealthAugust 8, 2024 - EE223 Cost-Effectiveness of Olorofim in Invasive Aspergillosis Patients Lacking Suitable Alternative Treatment Options from a US Payer Perspective
- Walsh et al.
Value in Health - EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective
- Liu et al.
Value in Health - EE393 Assessing Cost-Effectiveness in Diabetes Management: A US Healthcare Payer’s Perspective on 15MG Tirzepatide Versus 1MG Semaglutide
- R Almasuood
Value in Health - EE3 Cost Effectiveness Model on Four Preventive Treatment for Clostridioides Difficile Infection Recurrence From a US Payer Perspective
- Gómez-Lumbreras et al.
Value in Health - EE260 Cost-Effectiveness Analysis of Daratumumab Triplet Therapy Vs Carfilzomib Duplet Therapy in Patients with Relapsed or Refractory Multiple Myeloma in Egypt from Payer Perspective
- Elsisi et al.
Value in Health - EE2 A Cost-Effectiveness Analysis Comparing Obesity Drug Treatments from a U.S. Payer Perspective
- Gómez-Lumbreras et al.
Value in Health - HPR8 Drug Approvals for Advanced Breast Cancer in Brazil: Historical Perspective and Comparative Cost-Effectiveness Analysis
- Goncalves et al.
Value in Health - Patient-Informed Value Elements in Cost-Effectiveness Analyses of Major Depressive Disorder Treatment: A Literature Review and Synthesis
- Slejko et al.
Value in HealthJune 6, 2024 - Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study
- Chen et al.
Value in HealthMarch 26, 2024 - EE170 A Cost-Effectiveness Analysis, with Public Healthcare Payers’ Perspective, of Oral Semaglutide Versus Luseogliflozin Hydrate for Patients with Type 2 Diabetes Mellitus in a Japanese Clinical Setting
- Ota et al.
Value in Health - RWD162 Evolution of Breast Cancer Treatment Cost in the Last 36 Months: An Analysis From a Health Payer Perspective in Brazil
- Reis Neto et al.
Value in Health - Economic evaluation of Fasting Mimicking Diet vs. standard care in diabetic patients on dual or triple medications at baseline in the US: A cost-utility analysis
- Habka et al.
Value in HealthSeptember 26, 2024 - Discriminatory Properties of Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study
- Klimchak et al.
Value in HealthJuly 31, 2024 - EE81 Cost-Effectiveness of CDK 4/6I for the Treatment of Postmenopausal Patients With Advanced Breast Cancer HR-Positive, HER2-Negative From the Point of View of the Payer of the Public Health System in Panama
- Castillo-Fernandez et al.
Value in Health - MT45 Cost-Effectiveness Analysis of Left Atrial Appendage Closure (LAAC) Device Vesus Warfarin and New Oral Anticoagulants (NOACS) in Patients with Atrial Fibrillation (AF) - Large Brazilian Healthcare Payer Perspective
- Tortele et al.
Value in Health - EE429 Optimizing Multicancer Early Detection (MCED) Testing Based on Patient Stratification: A Comprehensive Analysis of Economic and Clinical Impact from a US Payer Perspective
- Long et al.
Value in Health - How Many Monte Carlo Samples are Needed for Probabilistic Cost-Effectiveness Analyses?
- Reza Yaesoubi
Value in HealthJuly 5, 2024 - The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers
- Teppala et al.
Value in HealthJuly 5, 2024 - Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework
- Jiao et al.
Value in HealthJanuary 5, 2024 - RWD178 Costs of Cancer Care Across the Disease Continuum: An Analysis From a Health Payer Perspective in Brazil
- Dos Reis et al.
Value in Health - Estimating the US Baseline Distribution of Health Inequalities Across Race, Ethnicity, and Geography for Equity-Informative Cost-Effectiveness Analysis
- Kowal et al.
Value in HealthJuly 4, 2023 - Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses
- Xie et al.
Value in HealthMarch 26, 2024 - EE343 Cost-Utility and Cost-Effectiveness of Rapid Recovery After Joint Replacement: The Payer's Perspective
- I. Salvi
Value in Health - EE494 A Budget Impact Analysis of Newer Pneumococcal Conjugate Vaccine Use in All US Adults Aged 50-64 Years Old Compared to Current Recommendations from US Payer Perspective
- Vadlamudi et al.
Value in Health - Can Generalized Cost-Effectiveness Analysis Leverage Meaningful Use of Novel Value Elements in Pharmacoeconomics to Inform Medicare Drug Price Negotiation?
- Padula et al.
Value in HealthApril 25, 2024 - EE454 Cost-Effectiveness of Screening for Atrial Fibrillation Utilizing the Unafied-7 Algorithm Versus Usual Care in Individuals Aged 65 from a US Payer Perspective
- Subash et al.
Value in Health - EE711 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Tiotropium/Olodaterol (TIO/OLO) in Patients With COPD: United Kingdom Payer Perspective
- Kendall et al.
Value in Health - EE85 A Cost-Utility Analysis Comparing a Clinical Decision Support Software to Prescriber Decision Alone for Drug-Drug Interactions from an U.S. Payer Perspective
- Gómez-Lumbreras et al.
Value in Health - Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States
- Oluwole et al.
Value in HealthApril 16, 2024 - HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective
- Chu et al.
Value in Health - The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics
- Kogut et al.
Value in HealthDecember 22, 2022 - EE53 A Cost of Illness Analysis of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) With FLT3 Mutations in Chile: A Public Payer Perspective
- Ariza et al.
Value in Health
